Literature DB >> 30523543

Natural history of bulla neogenesis for primary spontaneous pneumothorax: a propensity score analysis.

Kenji Tsuboshima1, Yasumi Matoba2, Teppei Wakahara2, Yoshimasa Maniwa3.   

Abstract

OBJECTIVE: For patients with recurrent primary spontaneous pneumothorax, surgery has been thought to be an acceptable treatment. However, even if bulla is completely resected, postoperative recurrence is relatively common due to bulla neogenesis. Bulla neogenesis seems to develop naturally in younger patients compared with the elderly, as theorized till date. If the complete development of bulla neogenesis is confirmed, surgical resection can be performed as the radical treatment. Then, we evaluated the relationship between bulla neogenesis and age.
METHODS: Between February 2009 and July 2018, we consecutively enrolled 276 patients who underwent primary bullectomy for primary spontaneous pneumothorax in our hospital. Finally, high-resolution computed tomography findings/observations of 155 eligible patients were evaluated retrospectively. The relationship between bulla neogenesis and age was evaluated using univariate and multivariate analyses and an inverse probability of treatment-weighted method using the propensity score.
RESULTS: The study included 58 patients aged < 20 years and 97 aged ≥ 20 years. Bulla neogenesis was present in 34 patients (21.9%). Bulla neogenesis developed significantly at age < 20 compared with age ≥ 20 (44.8 vs. 8.2%). Univariate and multivariate analyses showed that age < 20 years was a significant factor associated with bulla neogenesis (P < 0.001 and P = 0.018, respectively). The inverse probability of treatment-weighted method showed that age < 20 years was a significant factor associated with bulla neogenesis (P = 0.0057, hazard ratio 4.79).
CONCLUSIONS: Surgical treatment may be delayed in young patients (age < 20 years), because bulla neogenesis is not completely developed by this time for primary spontaneous pneumothorax.

Entities:  

Keywords:  Age; Bulla neogenesis; Natural history; Primary spontaneous pneumothorax; Propensity score

Mesh:

Year:  2018        PMID: 30523543     DOI: 10.1007/s11748-018-1046-3

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  21 in total

1.  Management of spontaneous pneumothorax: British Thoracic Society Pleural Disease Guideline 2010.

Authors:  Andrew MacDuff; Anthony Arnold; John Harvey
Journal:  Thorax       Date:  2010-08       Impact factor: 9.139

2.  Cause and management of recurrent primary spontaneous pneumothorax after thoracoscopic stapler blebectomy.

Authors:  Takashi Muramatsu; Mie Shimamura; Motohiko Furuichi; Tatsuhiko Nishii; Shinji Takeshita; Shinichiro Ishimoto; Hiroaki Morooka; Yoko Tanaka; Chiyoshi Yagasaki; Kazumitsu Ohmori; Motomi Shiono
Journal:  Asian J Surg       Date:  2011-04       Impact factor: 2.767

3.  Simple aspiration and drainage and intrapleural minocycline pleurodesis versus simple aspiration and drainage for the initial treatment of primary spontaneous pneumothorax: an open-label, parallel-group, prospective, randomised, controlled trial.

Authors:  Jin-Shing Chen; Wing-Kai Chan; Kung-Tsao Tsai; Hsao-Hsun Hsu; Chien-Yu Lin; Ang Yuan; Wen-Jone Chen; Hong-Shiee Lai; Pan-Chyr Yang
Journal:  Lancet       Date:  2013-03-12       Impact factor: 79.321

4.  Recurrence of primary spontaneous pneumothorax in young adults and children.

Authors:  Dongsub Noh; Sungsoo Lee; Seok Jin Haam; Hyo Chae Paik; Doo Yun Lee
Journal:  Interact Cardiovasc Thorac Surg       Date:  2015-04-29

5.  Staple line coverage after bullectomy for primary spontaneous pneumothorax: a randomized trial.

Authors:  Sungsoo Lee; Hyeong Ryul Kim; Sukki Cho; Dong Myung Huh; Eung Bae Lee; Kyoung Min Ryu; Deug Gon Cho; Hyo Chae Paik; Dong Kwan Kim; Sung-Ho Lee; Jeong Su Cho; Jae Ik Lee; Ho Choi; Kwhanmien Kim; Sanghoon Jheon
Journal:  Ann Thorac Surg       Date:  2014-10-23       Impact factor: 4.330

Review 6.  ERS task force statement: diagnosis and treatment of primary spontaneous pneumothorax.

Authors:  Jean-Marie Tschopp; Oliver Bintcliffe; Philippe Astoul; Emilio Canalis; Peter Driesen; Julius Janssen; Marc Krasnik; Nicholas Maskell; Paul Van Schil; Thomy Tonia; David A Waller; Charles-Hugo Marquette; Giuseppe Cardillo
Journal:  Eur Respir J       Date:  2015-06-25       Impact factor: 16.671

7.  Risk factors for recurrence of primary spontaneous pneumothorax after thoracoscopic surgery.

Authors:  Haibo Huang; Hua Ji; Hui Tian
Journal:  Biosci Trends       Date:  2015-06       Impact factor: 2.400

Review 8.  Management of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statement.

Authors:  M H Baumann; C Strange; J E Heffner; R Light; T J Kirby; J Klein; J D Luketich; E A Panacek; S A Sahn
Journal:  Chest       Date:  2001-02       Impact factor: 9.410

9.  Surgical pleurodesis for Vanderschueren's stage III primary spontaneous pneumothorax.

Authors:  O Rena; F Massera; E Papalia; C Della Pona; M Robustellini; C Casadio
Journal:  Eur Respir J       Date:  2007-12-05       Impact factor: 16.671

10.  Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria.

Authors:  Hiroshi Katayama; Yukinori Kurokawa; Kenichi Nakamura; Hiroyuki Ito; Yukihide Kanemitsu; Norikazu Masuda; Yasuhiro Tsubosa; Toyomi Satoh; Akira Yokomizo; Haruhiko Fukuda; Mitsuru Sasako
Journal:  Surg Today       Date:  2015-08-20       Impact factor: 2.549

View more
  2 in total

1.  Contralateral bulla neogenesis associated with postoperative recurrences of primary spontaneous pneumothorax in young patients.

Authors:  Kenji Tsuboshima; Yasumi Matoba; Teppei Wakahara
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

2.  Risk factors of postoperative recurrence of primary spontaneous pneumothorax.

Authors:  Taiki Fujiwara; Kazuhisa Tanaka; Takahide Toyoda; Terunaga Inage; Yuichi Sakairi; Fumihiro Ishibashi; Hidemi Suzuki; Takahiro Nakajima; Ichiro Yoshino
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.